<DOC>
	<DOCNO>NCT02450578</DOCNO>
	<brief_summary>Study evaluate efficacy DSM265 causal prophylactic standardize validated Human Challenge model use direct venous inoculation aseptic , purified , cryopreserved , vialed Plasmodium falciparum sporozoite .</brief_summary>
	<brief_title>DSM265 Chemoprophylaxis Plasmodium Falciparum Malaria</brief_title>
	<detailed_description>This study follow First In Human dose-escalation study DSM265 ( 25 - 800 mg DSM265 ) Induced-Blood Stage Malaria Challenge study ( 150 mg DSM265 ) conduct healthy adult volunteer Australia . After identification efficacious DSM265 plasma concentration Induced-Blood Stage Malaria model , current study evaluate efficacy DSM265 causal prophylactic standardize validated Human Challenge model use direct venous inoculation aseptic , purified , cryopreserved , vialed Plasmodium falciparum sporozoite ( Challenge ) . Three sequential cohort healthy male woman volunteer , non-childbearing potential childbearing potential predefined accepted method contraception , plan order investigate three preventive condition regard administration DSM265 . Preventive administration study drug occur 1 7 day inoculum Plasmodium falciparum sporozoite Challenge , last cohort administer time point determine 2 previous cohort exceed 28 day challenge . The study also include cohort subject treat atovaquone-proguanil ( MalaroneÂ® ) use approve regimen chemoprophylaxis .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<mesh_term>Atovaquone , proguanil drug combination</mesh_term>
	<criteria>Good health base medical history physical examination Body mass index &gt; 18 &lt; 30 kg/m2 Lab result without clinically significant finding 28 day prior enrolment Negative drug screen test Females : negative pregnancy test screen day first dose DSM265 sporozoite challenge injection Sexually active male must agree use medically acceptable form contraception enrolment continue 12 week dose DSM265 Women may include either Identified child bear potential , child bear potential willing able practice one continuous acceptable method contraception ( must one failure rate le 1 % per year ) double barrier protection : Intrauterine device+condoms , Diaphragms+spermicidal gel/foam+condoms , Hormonal contraceptive ( oral , depot , patch , injectable vaginal ring ) stabilize least 30 day study drug + condom screen least 60 day dose DSM265 Agree allow investigator discuss medical history General Practitioner sign request release medical information concern contraindication participation study Able willing comply study requirement duration study Agree undergo study procedure , attend study visit stay overnight observation require , last follow visit Willing undergo sporozoite challenge Able willing answer question inform consent quiz correctly demonstrate understand mean study procedure Able willing sign inform consent form Reachable ( 24/7 ) mobile phone email whole study period Agree refrain blood donation course study end involvement study accord local national blood banking eligibility criterion ( currently 4 year Germany ) Willing take curative regimen Riamet another register antimalarial necessary Any history malaria Plans travel malaria endemic region study period last follow visit plan travel outside Germany challenge period unable closely follow social , geographic psychological reason Previous participation malaria vaccine study control human malaria infection study Participation clinical study within 30 day enrolment study , plan participate another investigational vaccine/drug research study period . Woman breastfeed plan become pregnant study Positive human immunodeficiency virus , seropositive hepatitis B surface antigen Hepatitis C virus test Any confirmed/suspected immunosuppressive immunodeficient state , include human immunodeficiency virus infection , asplenia , recurrent , severe infection chronic ( 14 day ) immunosuppressant medication within 6 month enrolment ( inhaled topical steroid allow ) History serious psychiatric condition may affect participation study , precludes compliance protocol ; past present psychosis ; disorder require lithium ; within 5 year prior enrolment , history suicide plan attempt . History convulsion severe head trauma Symptoms , physical sign lab value suggestive systemic disorder include renal , hepatic , cardiovascular , pulmonary , skin , immunodeficiency , condition could interfere interpretation study result compromise health History cancer ( except basal cell carcinoma skin ) , diabetes mellitus arrhythmias document prolonged QTFinterval ( &gt; 450msec ) Clinically significant abnormality electrocardiogram screening : pathologic Q wave , prolong QT interval , significant STT wave change , leave ventricular hypertrophy , nonsinus rhythm except isolated premature atrial contraction , right leave bundle branch block , advance AV heart block ( type 2 type 3 ) In moderate risk high category fatal nonfatal cardiovascular event within 5 year ( &gt; 10 % ) determine noninvasive criterion cardiac risk Positive family history relatives &lt; 50 year cardiac disease History psoriasis porphyria , may exacerbate chloroquine History splenectomy Sickle cell anaemia red blood cell disorder History allergy contraindication contraindication use chloroquine phosphate , atovaquoneproguanil ( cohort 1B ) , artemether lumefantrine Use prescription drug ( except contraception ) , herbal supplement overthecounter medication 4 week dose 5x halflives , whichever long Use anticipate use medication know cause drug reaction rescue medication Malarone , cimetidine , metoclopramide , antacid take point study period . Intake grapefruit , grapefruit juice , Seville orange product contain ingredient within 7 day first drug administration Use chronic immunosuppressive drug , immune modifying drug within 6 month enrolment ( inhaled topical corticosteroid oral antihistaminic allow ) and/or study period Use systemic antibiotic know antimalarial activity within 30 day study enrolment ( e.g . trimethoprimsulfamethoxazole , doxycycline , tetracycline , clindamycin , erythromycin , fluoroquinolones , azithromycin ) and/or study period Use immunoglobulins blood product 3 month prior enrolment Suspected/known inject drug abuse 5 year precede enrolment Current smoking 10 cigarette equivalent per day Plan major surgery enrolment follow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>